Efficacy News and Research

RSS

Spectrum Pharmaceuticals initiates enrollment in Phase 2b ozarelix study for prostate cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.

15 Aug 2012

Drug-eluting stents cleared for diabetes patients

All currently available drug-eluting stents are more effective than bare metal stents (BMS) for patients with diabetes, research suggests.

14 Aug 2012

Physiotherapy beneficial for Parkinson’s patients

Results from a systematic review and meta-analysis published in the BMJ suggest that physiotherapy interventions benefit Parkinson’s disease patients, at least in the short term.

14 Aug 2012

Tofacitinib efficacy suggested for rheumatoid arthritis

The novel oral Janus kinase inhibitor tofacitinib significantly reduces signs and symptoms of rheumatoid arthritis, report two phase III trials published in TheNew England Journal of Medicine.

13 Aug 2012

FDA accepts Teva's NDA for Quartette oral contraceptive

Teva Women's Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for Quartette (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets).

13 Aug 2012

Wound dressing containing ionic silver capable of killing multidrug-resistant organisms

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced in vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of multidrug-resistant organisms (MDROs), commonly referred to as 'superbugs.' The study results were published in the August issue of the International Wound Journal.

13 Aug 2012

Epigenetic factors involved in treatment-resistance to schizophrenia drugs

Researchers at Mount Sinai School of Medicine may have discovered why certain drugs to treat schizophrenia are ineffective in some patients. Published online in Nature Neuroscience, the research will pave the way for a new class of drugs to help treat this devastating mental illness, which impacts one percent of the world's population, 30 percent of whom do not respond to currently available treatments.

13 Aug 2012

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Acorda Therapeutics, Inc. today announced top line results from a post-marketing commitment study evaluating a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis. The study failed to confirm efficacy of the 5mg dose.

13 Aug 2012

Orally effective FluCide anti-influenza drug candidate

NanoViricides, Inc. announced today that an anti-influenza drug candidate under its FluCide program is effective when given orally. The Company has received information that a FluCide drug candidate designed for oral administration has shown very strong efficacy in corresponding animal studies.

13 Aug 2012

Study assesses gender differences in the efficacy of antiretroviral treatment

Women comprise nearly half of the HIV-infected population worldwide, but these 15.5 million women tend to be under-represented in clinical trials of anti-HIV drug therapies. The U.S. Food and Drug Administration (FDA) has created a database from 40 clinical studies to assess gender differences in the efficacy of antiretroviral treatments.

12 Aug 2012

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Pfizer Inc. announced that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.

12 Aug 2012

Evidence is lacking for patient safety strategies

Evidence for the efficacy of in-hospital strategies to improve patient safety culture are lacking, show the results of a systematic review.

10 Aug 2012

Anemia prevention in pregnancy: an interview with Juan Pablo Peña-Rosas, WHO

Anaemia is a condition in which the number of red blood cells in the body is lower than normal or these have lower amounts of haemoglobin, a protein that is involved in the oxygen exchange of the body.

10 Aug 2012

Risk model predicts illness after ambulatory surgery

A marked proportion of patients undergoing ambulatory surgery suffer postdischarge nausea and vomiting, say US scientists who have developed a simplified risk score to identify patients who may benefit from long-acting prophylactic therapy.

9 Aug 2012

Dabigatran ‘still effective in obese’

The oral direct thrombin inhibitor dabigatran is an effective thromboprophylactic therapy for patients undergoing total hip or knee replacement regardless of their body mass index, researchers assert.

9 Aug 2012

Combination of two existing pharmaceutical drugs shows promise against cocaine addiction

A fine-tuned combination of two existing pharmaceutical drugs has shown promise as a potential new therapy for people addicted to cocaine—a therapy that would reduce their craving for the drug and blunt their symptoms of withdrawal.

9 Aug 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Adding motesanib to carboplatin–paclitaxel does not boost overall survival in patients with advanced nonsquamous non-small-cell lung cancer, including those with adenocarcinoma, say MONET1 investigators.

8 Aug 2012

‘Green’ disinfectant shows promise against hospital-acquired infections

Research shows that the polyhexamethylene-guanidine hydrochloride-based disinfectant Akwaton effectively destroys Bacillus subtilis spores even at low concentrations.

8 Aug 2012

Omeros completes enrollment in first of two OMS103HP Phase 3 meniscectomy trials

Omeros Corporation today reported the completion of enrollment in the first of two planned Phase 3 clinical trials evaluating OMS103HP in patients undergoing arthroscopic partial meniscectomy surgery.

8 Aug 2012

Patients in clinical trials of new targeted cancer therapies appear to have lower risk of side-effects

Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.

8 Aug 2012